

ASX Announcement

4 April 2024

Dispatch of Entitlement Offer Prospectus

Melbourne, Australia – 4 April 2024: OncoSil Medical Limited (ASX: OSL) (**OncoSil** or the **Company**) refers to its announcement dated 20 March 2024 in relation to the Company's non-renounceable entitlement offer to eligible shareholders to raise up to approximately \$5.65 million (**Entitlement Offer**), and is pleased to confirm that in accordance with the indicative timetable, the Entitlement Offer Prospectus together with accompanying personalised Entitlement and Acceptance Form and a blank Shortfall Application Form have been dispatched today to eligible shareholders.

Eligible shareholders are advised that the Entitlement Offer is **now open** for applications and will **close at 5pm (AEST) on 24 April 2024**. Personalised **Entitlement and Acceptance Forms** are also available for registered users at www.investorserve.com.au. Shareholders can register for online access at www.investorserve.com.au.

Indicative Entitlement Offer Timetable

Event	Date
Placement and Entitlement Offer announcement	20 March 2024
Lodgement of Prospectus with ASIC and ASX	25 March 2024
Record Date	28 March 2024
Dispatch of Prospectus and Entitlement Offer opens	4 April 2024
Entitlement Offer closes	24 April 2024
Allotment and issue of New Shares under Entitlement Offer	2 May 2024
Expected normal trading of New Shares under Entitlement Offer	3 May 2024

Note: Dates / times are indicative and subject to change. All times / dates are in reference to Melbourne Time

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

<p>Mr Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
---	---	--

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

¹ www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/

4 April 2024

Dear Shareholder

Ineligible Shareholders - OncoSil Medical Limited Entitlement Offers

On 20 March 2024, **OncoSil Medical Limited** ACN 113 824 141 (**Company**) announced that it is undertaking a non-renounceable pro-rata entitlement offer of **1 New Share for every 2 Shares** held at the Record Date of 7.00pm (AEDT) on 28 March 2024 (**Record Date**), at an Issue Price of \$0.005 (0.5 cents) per New Share (**Entitlement**), together with 1 Long Dated Option and 2 Short Dated Options for every 2 New Shares issued under the offer (**Rights Issue Offer**). The Rights Issue Offer is to raise up to approximately \$5.65 million (before costs), the maximum being on the basis that no more than approximately 1,129,413,846 New Shares will be issued pursuant to the Rights Issue Offer. The Rights Issue Offer is not underwritten.

Shareholders who subscribe for their full Entitlement will also be able to subscribe for Additional Shares at the same price (for which subscribers will also be issued 1 Long Dated Option and 2 Short Dated Options for every 2 Additional Shares issued) (**Top-Up Offer**).

The Directors have reserved the right for up to 3 months after the close of the Rights Issue Offer to place any shortfall under the Rights Issue Offer, including after the Top-Up Offer (if any) at a price no less than the Issue Price.

A copy of the above announcement, together with further details of the Rights Issue Offer, are available on the Company's website www.oncosil.com and also on the ASX Announcements Platform. A copy of the Prospectus relating to the Rights Issue Offer has been lodged with ASIC and the ASX and is available for viewing on the ASX website and the Company's website.

Restrictions apply to eligibility to participate in the Rights Issue Offer. As permitted by law, the Company has decided, pursuant to ASX Listing Rule 7.7.1(a) and section 9A(3)(a) of the Corporations Act, that it is unreasonable to make the Rights Issue Offer to any Shareholder with a registered address outside Australia or New Zealand (retail and wholesale shareholders) as at the Record Date (namely 7.00pm (AEDT) on 28 March 2024), having regard to:

- (a) the relatively small number of Shareholders with addresses in such other countries as a proportion of total Shareholders in the Company;
- (b) the relatively small number and value of the Shares those Shareholders would be offered under the Rights Issue Offer; and
- (c) the cost to the Company of complying with applicable legal and regulatory requirements in such other countries.

Accordingly, the Rights Issue Offer (including the Top-Up Offer) will not be made to shareholders resident in the jurisdiction in which your shareholding is registered.

This letter is to inform you that according to our records, under the terms of the Rights Issue Offer **you are an ineligible shareholder** and therefore not eligible to subscribe for New Shares and New Options and no Entitlements will be issued to you. Accordingly, the Company is not extending the Rights Issue Offer and Top-Up Offer to you and this letter is not an offer to issue New Shares,

New Options or Entitlements to you, nor an invitation for you to apply for new Shares.

You are not required to do anything in response to this letter.

If you have any questions, please call the Company's share registry, Boardroom Pty Limited, on 1300 737 760 (from within Australia) or +61 2 9290 9600 (from outside Australia) between 9:00 am and 5:00 pm.

For other questions, you should contact your stockbroker, accountant, taxation advisor, financial advisor or other professional advisor.

Yours faithfully,

Christian Dal Cin
Company Secretary